Branebrutinib治疗类风湿关节炎的2a期随机双盲安慰剂对照研究
这项2a期随机双盲安慰剂对照研究评估了不可逆BTK抑制剂branebrutinib在甲氨蝶呤应答不佳的类风湿关节炎患者中的疗效与安全性。两组不良事件发生率相似,未报告严重不良事件或死亡。
要点
- branebrutinib 9mg每日一次治疗12周未达到主要终点ACR50应答率。
- 两组不良事件发生率相似,未报告严重不良事件或死亡。
核心结论
- branebrutinib与安慰剂在所有临床疗效指标上均无显著差异。
- branebrutinib 12周安全性良好,耐受性佳。
研究设计与样本
- 2a期随机双盲安慰剂对照研究,在美国、波兰和西班牙24个中心进行。
- 纳入85例18-75岁、符合2010年ACR-EULAR分类标准、病程小于4年且甲氨蝶呤应答不佳的类风湿关节炎患者。
- 患者按3:1随机接受branebrutinib 9mg每日一次(n=64)或安慰剂(n=21)治疗12周。
- 主要终点为第12周ACR50应答率,在全分析集评估。
主要发现
- 不良事件发生率branebrutinib组为30/64(47%),安慰剂组为8/21(38%)。
- 未报告严重不良事件或死亡。
临床怎么用
- 对于甲氨蝶呤应答不佳的类风湿关节炎患者,branebrutinib 9mg每日一次治疗12周未显示优于安慰剂的疗效。
- branebrutinib 12周安全性良好,但需进一步研究验证其疗效。
局限性
- 仅报告双盲治疗期12周数据,开放标签期数据未报告。
- 样本量较小(branebrutinib组64例,安慰剂组21例)。
- 研究未纳入有类风湿关节炎 lived experience 的患者参与设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Branebrutinib, an oral, highly selective, and irreversible Bruton's tyrosine kinase inhibitor, is a potential candidate for rheumatoid arthritis treatment as Bruton's tyrosine kinase has a role in B-cell activation, autoantibody production, and proinflammatory cytokine release, all of which are implicated in rheumatoid arthritis disease activity and progression. This study assessed the efficacy and safety of branebrutinib in patients with rheumatoid arthritis and an inadequate response to methotrexate. METHODS: This phase 2a, randomised, double-blind, placebo-controlled study was designed to assess the efficacy and safety of branebrutinib in patients with rheumatoid arthritis, systemic lupus erythematosus, or primary Sjögren's disease. Here, we report the results of the rheumatoid arthritis substudy, done in the USA, Poland, and Spain across 24 sites. The study included a 12-week double-blind treatment period followed by an additional 12-week open-label period with abatacept treatment. Only data for the double-blind treatment period are reported here. Eligible patients were aged 18-75 years, met the 2010 American College of Rheumatology (ACR)-European Alliance of Associations for Rheumatology criteria for rheumatoid arthritis, had disease duration less than 4 years, and had inadequate response to methotrexate. Patients were randomly assigned (3:1) to receive branebrutinib 9 mg once daily or placebo for 12 weeks. Randomisation was carried out centrally according to a computer-generated block randomisation scheme using interactive response technology. All parties were masked to treatment allocation. The primary endpoint was the proportion of patients who had 50% improvement in the ACR response criteria (ACR50) at week 12, assessed in all participants randomly assigned to treatment (full analysis set). Safety was assessed in patients who received at least one dose of branebrutinib or placebo. This trial was registered with ClinicalTrials.gov, NCT04186871. Patients with lived experience of rheumatoid arthritis were not involved in the study design. FINDINGS: Between Jan 7, 2020, to Dec 5, 2022, 85 patients were randomly assigned to receive branebrutinib (n=64) or placebo (n=21). 63 (74%) of 85 patients were female, 22 (26%) were male, 80 (94%) were White, and the mean age was 49·1 years (SD 12·0). The primary endpoint of ACR50 response at week 12 was not met; 12 (19%) of 64 patients had an ACR50 response in the branebrutinib group compared with seven (33%) of 21 patients in the placebo group (p=0·16). Adverse events were similar between the two groups (30 [47%] of 64 in the branebrutinib group and 8 [38%] of 21 in the placebo group), with no reported serious adverse events or deaths. INTERPRETATION: There was no significant difference between branebrutinib and placebo for any clinical efficacy measures. The 12-week safety profiles were similar between treatment groups, and branebrutinib was well tolerated with a favourable safety profile. FUNDING: Bristol Myers Squibb.
引用
- Østergaard M, Haavardsholm EA, Nowak M, et al. Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Rheumatol. 2026. PMID: 42081904. doi:10.1016/S2665-9913(25)00374-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。